Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
Montgomery, Bruce, Eisenberger, Mario A, Rettig, Matthew B, Chu, Franklin, Pili, Roberto, Stephenson, Joseph J, Vogelzang, Nicholas J, Koletsky, Alan J, Nordquist, Luke T, Edenfield, William J, Mamlouk, Khalid, Ferrante, Karen J, Taplin, Mary-Ellen
Published in Clinical cancer research (15.03.2016)
Published in Clinical cancer research (15.03.2016)
Get full text
Journal Article
Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer
Taplin, Mary-Ellen, Antonarakis, Emmanuel S., Ferrante, Karen J., Horgan, Kerry, Blumenstein, Brent, Saad, Fred, Luo, Jun, de Bono, Johann S.
Published in European urology (01.12.2019)
Published in European urology (01.12.2019)
Get full text
Journal Article
A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors
MOULDER, Stacy L, MAHANY, John J, SULLIVAN, Daniel M, LUSH, Richard, ROCHA-LIMA, Caio, LANGEVIN, Michael, FERRANTE, Karen J, BARTKOWSKI, Lisa Michele, KAJIJI, Shama M, NOE, Dennis A, PAILLET, Simone
Published in Clinical cancer research (01.11.2004)
Published in Clinical cancer research (01.11.2004)
Get full text
Journal Article
Androgen receptor modulation optimized for response: Splice variant (ARMOR3-SV)–Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant
Taplin, Mary-Ellen, Antonarakis, Emmanuel S., Dransfield, Daniel T., Ferrante, Karen J., De Bono, Johann Sebastian
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article
Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant (ARMOR3-SV)
Antonarakis, Emmanuel S., De Bono, Johann S., Ferrante, Karen J., Horgan, Kerry, Luo, Jun, Saad, Fred, Taplin, Mary-Ellen
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC)
Taplin, Mary-Ellen, Antonarakis, Emmanuel S., Ferrante, Karen J., Horgan, Kerry, Blumenstein, Brent A., Saad, Fred, Luo, Jun, De Bono, Johann S.
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
Androgen Receptor Modulation Optimized for Response in Splice Variant (ARMOR3-SV): Randomized, open-label, multicenter, controlled study of galeterone versus enzalutamide (enz) in men expressing AR-V7 splice variant (SV), metastatic castrate resistant prostate cancer (mCRPC)
Roberts, Jennifer, Dhillon, Reena, Dransfield, Daniel T., Mamlouk, Khalid Kevin, Ferrante, Karen J.
Published in Journal of clinical oncology (01.03.2015)
Published in Journal of clinical oncology (01.03.2015)
Get full text
Journal Article
Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2
Taplin, Mary-Ellen, Chu, Franklin, Cochran, James S., Ferrante, Karen J., Lipsitz, David Uri, Roberts, Jennifer, Sartor, Oliver, Heath, Elisabeth I.
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
N-(3-ETHYNYLPHENYL)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE FOR USE IN THE TREATMENT OF NSCLC
MOYER, James, D, NORRIS, Timothy, FOSTER, Barbara, A, KAJIJI, Shama, M, MORIN, Michael, J, FERRANTE, Karen, J, SILBERMAN, Sandra, L, RAGGON, Jeffrey, W, CONNELL, Richard, D
Year of Publication 07.12.2016
Get full text
Year of Publication 07.12.2016
Patent
STABLE POLYMORPH OF N−(3−ETHYNYLPHENYLAMINO)−6,7−BIS(2−METHOXYETHOXY)−4−QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF
KAJIJI SHAMA M, FERRANTE KAREN J, NORRIS TIMOTHY, CONNELL RICHARD D, MORIN MICHAEL J, RAGGON JEFFREY W, MOYER JAMES D, SILBERMAN SANDRA L, FOSTER BARBARA A
Year of Publication 31.10.2016
Get full text
Year of Publication 31.10.2016
Patent
STABLE POLYMORPH OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF
CONNELL, RICHARD D, FERRANTE, KAREN J, SILBERMAN, SANDRA L, MOYER, JAMES D, RAGGON, JEFFREY W, FOSTER, BARBARA A, KAJIJI, SHAMA M, NORRIS, TIMOTHY, MORIN, MICHAEL J
Year of Publication 03.01.2012
Get full text
Year of Publication 03.01.2012
Patent
Pharmaceutical uses of N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine
KAJIJI, SHAMA, M, RAGGON, JEFFREY, W, FERRANTE, KAREN, J, MORIN, MICHAEL, J, CONNELL, RICHARD, D, MOYER, JAMES, D, NORRIS, TIMOTHY, SILBERMAN, SANDRA, L, FOSTER, BARBARA, A
Year of Publication 27.07.2011
Get full text
Year of Publication 27.07.2011
Patent
Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
KAJIJI, SHAMA, M, RAGGON, JEFFREY, W, FERRANTE, KAREN, J, MORIN, MICHAEL, J, CONNELL, RICHARD, D, MOYER, JAMES, D, NORRIS, TIMOTHY, SILBERMAN, SANDRA, L, FOSTER, BARBARA, A
Year of Publication 20.07.2011
Get full text
Year of Publication 20.07.2011
Patent
STABLE POLYMORPH OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF
MOYER, James, D, NORRIS, Timothy, FOSTER, Barbara, A, KAJIJI, Shama, M, MORIN, Michael, J, FERRANTE, Karen, J, SILBERMAN, Sandra, L, RAGGON, Jeffrey, W, CONNELL, Richard, D
Year of Publication 10.05.2011
Get full text
Year of Publication 10.05.2011
Patent
Procedimiento para producir el polimorfo b de hidrocloruro de n-(3-etinilfenil)-6,7-bis(2-metoxietoxi)-4-quinazolinamina por recristalizacion del hidrocloruro de n-(3-etinilfenil)-6,7-bis(2-metoxietoxi)-4-quinazolinamina en un solvente que contiene etanol y agua (div. sol. n° 3107-00)
RICHARD D. CONNELL, BARBARA A. FOSTER, JEFFREY W. RAGGON, , TIMOTHY NORRIS, SHAMA M. KAJIJI, , KAREN J. FERRANTE, MICHAEL J. MORIN, SANDRA L. SILBERMAN, JAMES D. MOYER
Year of Publication 01.04.2011
Get full text
Year of Publication 01.04.2011
Patent
Pharmaceutical uses of N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine
KAJIJI, SHAMA, M, RAGGON, JEFFREY, W, FERRANTE, KAREN, J, MORIN, MICHAEL, J, CONNELL, RICHARD, D, MOYER, JAMES, D, NORRIS, TIMOTHY, SILBERMAN, SANDRA, L, FOSTER, BARBARA, A
Year of Publication 09.03.2011
Get full text
Year of Publication 09.03.2011
Patent
Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
KAJIJI, SHAMA, M, RAGGON, JEFFREY, W, FERRANTE, KAREN, J, MORIN, MICHAEL, J, CONNELL, RICHARD, D, MOYER, JAMES, D, NORRIS, TIMOTHY, SILBERMAN, SANDRA, L, FOSTER, BARBARA, A
Year of Publication 21.07.2010
Get full text
Year of Publication 21.07.2010
Patent
Stöðug fjölbrigði N-(3-etýnylfenýl)-6,7-bis)2-metoxýetoxy)-4-qínazólínamín hýdróklóríðs, aðferðir við framleiðslu þess og notkun til lyfjagerðar
TIMOTHY NORRIS, JEFFREY W. RAGGON, BARBARA A. FOSTER, KAREN J. FERRANTE, RICHARD D. CONNELL, JAMES D. MOYER, SHAMA M. KAJIJI, SANDRA L. SILBERMAN, MICHAEL J. MORIN
Year of Publication 15.04.2010
Get full text
Year of Publication 15.04.2010
Patent